BioSpace News Archive

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the full year 2021 on Thursday, March 24, 2022, after the market close.

Geron Corporation (Nasdaq: GERN) today announced that it will release its fourth quarter and full year 2021 financial results after the market closes on Thursday, March 10, 2022.

Today, the U.S. Food and Drug Administration finalized guidance to help companies prepare to quickly and effectively remove violative products from the market.

Pfizer Canada ULC is recalling all lots of Accuretic medication in 10/12.5 mg, 20/12.5 mg and 20/25 mg strengths due to the presence of a nitrosamine impurity above the acceptable level.

IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced the appointment of David V. Smith, MBA to its Board of Directors.

MacroGenics, Inc., a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, announced that the Company’s management will participate in the following investor conferences in March 2022:

Artivion, Inc., a leading cardiac and vascular surgery company focused on aortic disease, announced that it will participate virtually at the upcoming Oppenheimer 32nd Annual Healthcare Conference.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a precision oncology company focused on developing purpose-built therapies to overcome tumor resistance and improve outcomes for patients with cancer, today reported financial results for the quarter and year ended December 31, 2021 and highlighted recent corporate progress.

Puma Biotechnology, Inc., a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2021.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced its preliminary unaudited fourth quarter and full year 2021 financial results.